Form 4: Sagimet Biosciences CEO Sells Shares
Insider Transaction (Form 4)
David Happel, President & CEO and a Director of Sagimet Biosciences Inc., sold 64,051 shares of common stock on July 20, 2026 for $7.76 per share.
Summary
- Open-market sale: disposed of 64,051 Series A Common Stock at $7.76 ($497,068) on July 20, 2026; holds 741,570 after (Direct).
Sentiment
Score: 4
Explanation: StockSavvy.ai views this as a mildly negative signal: an insider sold $497,068 of stock on the open market.
Insider Transactions
David Happel — Director, Officer (President & CEO)
| Date | Transaction | Security | Shares | Price | Value | Held After |
|---|---|---|---|---|---|---|
| 2026-07-20 | Open-market sale | Series A Common Stock | 64,051 | $8 | $497.1K | 741,570 |
Key Dates
| Date | Description |
|---|---|
| 2026-07-20 | Open-market sale (64,051 shares) |
Keywords
insider transaction, Form 4, SGMT, Sagimet Biosciences Inc., bearish, David Happel
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.